Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial

Ettore Malacco, Stefano Omboni, Gianfranco Parati

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 150 or 300 mg plus HCTZ. Rate of office blood pressure (BP) response (zofenopril: 68% versus irbesartan: 70%; p = 0.778) and 24-hour BP response (zofenopril: 85% versus irbesartan: 84%; p = 0.781) was similar between the two treatment groups. Cardiac and renal damage was equally reduced by both treatments, whereas the rate of carotid plaque regression was significantly larger with zofenopril. In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression.

Original languageEnglish
Article number139465
JournalInternational Journal of Hypertension
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

zofenopril
irbesartan
Hydrochlorothiazide
Blood Pressure
Sodium Chloride Symporter Inhibitors
Kidney

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{bd0e3a7763b24aa68590675c93429ad1,
title = "Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial",
abstract = "In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 150 or 300 mg plus HCTZ. Rate of office blood pressure (BP) response (zofenopril: 68{\%} versus irbesartan: 70{\%}; p = 0.778) and 24-hour BP response (zofenopril: 85{\%} versus irbesartan: 84{\%}; p = 0.781) was similar between the two treatment groups. Cardiac and renal damage was equally reduced by both treatments, whereas the rate of carotid plaque regression was significantly larger with zofenopril. In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression.",
author = "Ettore Malacco and Stefano Omboni and Gianfranco Parati",
year = "2015",
doi = "10.1155/2015/139465",
language = "English",
volume = "2015",
journal = "International Journal of Hypertension",
issn = "2090-0384",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy

T2 - A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial

AU - Malacco, Ettore

AU - Omboni, Stefano

AU - Parati, Gianfranco

PY - 2015

Y1 - 2015

N2 - In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 150 or 300 mg plus HCTZ. Rate of office blood pressure (BP) response (zofenopril: 68% versus irbesartan: 70%; p = 0.778) and 24-hour BP response (zofenopril: 85% versus irbesartan: 84%; p = 0.781) was similar between the two treatment groups. Cardiac and renal damage was equally reduced by both treatments, whereas the rate of carotid plaque regression was significantly larger with zofenopril. In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression.

AB - In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 150 or 300 mg plus HCTZ. Rate of office blood pressure (BP) response (zofenopril: 68% versus irbesartan: 70%; p = 0.778) and 24-hour BP response (zofenopril: 85% versus irbesartan: 84%; p = 0.781) was similar between the two treatment groups. Cardiac and renal damage was equally reduced by both treatments, whereas the rate of carotid plaque regression was significantly larger with zofenopril. In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression.

UR - http://www.scopus.com/inward/record.url?scp=84939544773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939544773&partnerID=8YFLogxK

U2 - 10.1155/2015/139465

DO - 10.1155/2015/139465

M3 - Article

AN - SCOPUS:84939544773

VL - 2015

JO - International Journal of Hypertension

JF - International Journal of Hypertension

SN - 2090-0384

M1 - 139465

ER -